MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ejendo/lvae148

Медицинская библиотека · European journal of endocrinology · 2024

Targeted multiplex proteomics for the development and validation of biomarkers in primary aldosteronism subtyping.

Zhou Fangli, Ding Yun, Chen Tao, Tang Qiming, Zhang Jingjing, Thyparambil Sheeno, Jin Bo, Han Zhi, Chou C James, Schilling James, Luo Ruben Y, Tian Haoming, Sylvester Karl G, Whitin John C, Cohen Harvey J, McElhinney Doff B, Tian Li, Ling Xuefeng B, Ren Yan

СтатьяВалидационное исследованиеПеревод в очереди

Аннотация

OBJECTIVE

Primary aldosteronism (PA), a significant cause of secondary hypertension affecting ∼10% of patients with severe hypertension, exacerbates cardiovascular, and cerebrovascular complications even after blood pressure control. PA is categorized into two main subtypes: unilateral aldosterone-producing adenomas (APA) and bilateral hyperaldosteronism (BHA), each requiring distinct treatment approaches. Accurate subtype classification is crucial for selecting the most effective treatment. The goal of this study was to develop novel blood-based proteomic biomarkers to differentiate between APA and BHA subtypes in patients with PA.

DESIGN AND

METHODS

Five subtyping differential protein biomarker candidates (APOC3, CD56, CHGA, KRT5, and AZGP1) were identified through targeted proteomic profiling of plasma. The subtyping efficiency of these biomarkers was assessed at both the tissue gene expression and blood protein expression levels. To explore the underlying biology of APA and BHA, significant differential pathways were investigated.

RESULTS

The five-protein panel proved highly effective in distinguishing APA from BHA in both tissue and blood samples. By integrating these five protein biomarkers with aldosterone and renin, our blood-based predictive methods achieved remarkable receiver operating characteristic (ROC) area under the ROC curves of 0.986 (95% CI: 0.963-1.000) for differentiating essential hypertension from PA, and 0.922 (95% CI: 0.846-0.998) for subtyping APA versus BHA. These outcomes surpass the performance of the existing Kobayashi score subtyping system. Furthermore, the study validated differential pathways associated with the pathophysiology of PA, aligning with current scientific knowledge and opening new avenues for advancing PA care.

CONCLUSIONS

The new blood-based biomarkers for PA subtyping hold the potential to significantly enhance clinical utility and advance the practice of PA care.

Для цитирования: Zhou Fangli, Ding Yun, Chen Tao, Tang Qiming, Zhang Jingjing, Thyparambil Sheeno, Jin Bo, Han Zhi, Chou C James, Schilling James, Luo Ruben Y, Tian Haoming, Sylvester Karl G, Whitin John C, Cohen Harvey J, McElhinney Doff B, Tian Li, Ling Xuefeng B, Ren Yan. Targeted multiplex proteomics for the development and validation of biomarkers in primary aldosteronism subtyping.. European journal of endocrinology. 2024. DOI: 10.1093/ejendo/lvae148.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.